We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Adamas Pharmaceuticals announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical, a subsidiary of Osmotica Pharmaceuticals and completes the acquisition of the global rights to OSMOLEX ER®.